Dabigatran etexilate

Détails pour le produit réf. ABIN3220486
Inhibition Assay (InhA), Functional Studies (Func)
Fonction Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010.
Attributs du produit Tradename: PRADAXA
Source of Compound: synthetic, BIBR-1048
Target: Thrombin inhibitor
Receptor: Thrombin
Status: USAN
Purification All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
Pureté 98 %
Formula C34H41N7O5
Solubility Soluble in water
Sujet Angiogenesis
Poids moléculaire 627.73 g/mol
Numéro CAS 211915-06-9
Indications d'application Optimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Format Solid
Stock -20 °C
Stockage commentaire For the majority of compounds, they could be dissolved in DMSO or other organic solvent.
Their stock solution can be stored at -20°C for up to 3 months and aliquoted for sampling convenience.
Several freeze/thaw cycles should not damage the activity of our small molecule products.
However, in many instances the aqueous solutions of some compounds need to be made fresh and cannot be stored. For these compounds, their solution should be prepared just before use and stored no longer than 24 hours.
Date de péremption 24 months